熊肇军,董吁钢

• 1:中山大学附属第三医院心内科
• 2:中山大学附属第一医院心内科

摘要(Abstract)：

<正>心肌肥厚是高血压等患者心脑血管事件的独立危险因素。多种刺激如压力过负荷、神经体液因子以及心肌收缩蛋白基因突变等导致心肌细胞出现许多组织细胞形态学的适应性反应。肥大特征一般表现为:①心肌细胞体积增大;②蛋白质合成增加;③"胚胎期"基因再表达。大多数初期的心肌肥厚有代偿意义,持续性心肌肥厚最终可致扩张性心肌病、心力衰竭和猝死。心肌肥厚的分子机制非常复

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 熊肇军,董吁钢

参考文献(References)：

• [1]Ling H,Zhang T,Pereira L,et al.Requirement for Ca2+/calmodulin-dependent kinaseⅡin the transition from pressure overloadinduced cardiac hypertrophy to heart failure in mice[J].J Clin Invest,2009,119(5):1230-1240.
• [2]Kehat I,Molkentin JD.Molecular pathways underlying cardiac remodeling during pathophysiological stimulation[J].Circulation,2010,122(25):2727-2735.
• [3]Kehat I,Davis J,Tiburcy M,et al.Extracellular signal-regulated kinases1and2regulate the balance between eccentric and concentric cardiac growth[J].Circ Res,2011,108(2):176-183.
• [4]Kimura TE,Jin J,Zi M,et al.Targeted deletion of the extracellular signal-regulated protein kinase5attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart[J].Circ Res,2010,106(5):961-970.
• [5]Dingar D,Merlen C,Grandy S,et al.Effect of pressure overload-induced hypertrophy on the expression and localization of p38MAP kinase isoforms in the mouse heart[J].Cell Signal,2010,22(11):1634-1644.
• [6]Behr TM,Berova M,Doe CP,et al.p38mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease[J].Curr Opin Investig Drugs,2003,4(9):1059-1064.
• [7]Choukroun G,Hajjar R,Fry S,et al.Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases[J].J Clin Invest,1999,104(4):391-398.
• [8]Sadoshima J,Montagne O,Wang Q,et al.The MEKK1-JNK pathway plays aprotective role in pressure overload but does not mediate cardiac hypertrophy[J].J Clin Invest,2002,110(2):271-279.
• [9]Ma Y,Chen B,Liu D,et al.MG132treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1pathway[J].Biochem Pharmacol,2011,81(10):1228-1236.
• [10]Honsho S,Nishikawa S,Amano K,et al.Pressure-mediated hypertrophy and mechanical stretch induces IL-1release and subsequent IGF-1generation to maintain compensative hypertrophy by affecting Akt and JNK pathways[J].Circ Res,2009,105(11):1149-1158.
• [11]Rohini A,Agrawal N,Koyani CN,et al.Molecular targets and regulators of cardiac hypertrophy[J].Pharmacol Res,2010,61(4):269-280.
• [12]Liu Q,Chen X,Macdonnell SM,et al.Protein kinase C{alpha},but not PKC{beta}or PKC{gamma},regulates contractility and heart failure susceptibility:implications for ruboxistaurin as a novel therapeutic approach[J].Circ Res,2009,105(2):194-200.
• [13]Braz JC,Gill RM,Corbly AK,et al.Selective activation of PI3Kalpha/Akt/GSK-3beta signalling and cardiac compensatoryhypertrophy during recovery from heart failure[J].Eur J Heart Fail,2009,11(8):739-748.
• [14]Oudit GY,Penninger JM.Cardiac regulation by phosphoinositide3-kinases and PTEN[J].Cardiovasc Res,2009,82(2):250-260.
• [15]McMullen JR,Shioi T,Zhang L,et al.Phosphoinositide3-kinase(p110alpha)plays a critical role for the induction of physiological,but not pathological,cardiac hypertrophy[J].Proc Natl Acad Sci U S A,2003,100(21):12355-12360.
• [16]Freund C,Schmidt-Ullrich R,Baurand A,et al.Requirement of nuclear factor-NF-κB in angiotensinⅡ–and isoproterenol-induced cardiac hypertrophy in vivo[J].Circulation,2005,111(18):2319-2325.
• [17]Young D,Popovic ZB,Jones WK,et al.Blockade of NF-kappa B using I kappa B alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice[J].J Mol Biol,2008,381(3):559-568.
• [18]Giselle C,Mele′ndez,Jennifer L,et al.Interleukin6mediates myocardial fibrosis,concentric hypertrophy,and diastolic dysfunction in rats[J].Hypertension,2010,56(2):225-231.
• [19]Moe KT,Yin NO,Naylynn TM,et al.Nox2and Nox4mediate tumor necrosis factor-alpha-induced ventricular remodeling in mice[J].J Cell Mol Med,2011,15(12):2601-2613.
• [20]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state[J].Circulation,2007,115(11):1398-1407.
• [21]Xiong Z,Sun G,Zhu C,et al.Artemisinin,an anti-malarial agent,inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling[J].Eur J Pharmacol,2010,649(1-3):277-284.
• [22]Li H,Yin R,Chen D,et al.Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy[J].J Cell Biochem,2007,100(5):1086-1099.
• [23]Chen B,Ma Y,Meng R,et al.Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1signaling pathway in vitro[J].Acta Pharmacologica Sinica,2010,31(7):798-804.
• [24]Meng R,Pei Z,Zhang A,et al.AMPK activation enhances PPARa activity to inhibit cardiac hypertrophy via ERK1/2MAPK signaling pathway[J].Arch Biochem Biophys,2011,511(1-2):1-7.
• [25]陈广琴,刘晨,张成喜,等.HO-1在AMPK抑制心肌肥厚中的作用[J].中山大学学报,2010,31(5):614-618.
• [26]Zhang C,Pan S,Meng R,et al.Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats[J].Clin Exp Pharmacol Physiol,2011,38(1):55-62.
• [27]Li Q,Song XW,Zou J,et al.Attenuation of microRNA-1derepresses the cytoskeleton regulatory protein twinfilin-1to provoke cardiac hypertrophy[J].J Cell Sci,2010,123(Pt14):2444-2452.
• [28]Elia L,Contu R,Quintavalle M,et al.Reciprocal regulation of microRNA-1and insulin-like growth factor-1signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions[J].Circulation,2009,120(23):2377-2385.
• [29]Ikeda S,He A,Kong S,et al.MicroRNA-1negatively regulates expression of the hypertrophy-associa ted calmodulin and Mef2a genes[J].Mol Cell Biol,2009,29(8):2193-2204.
• [30]Li Q,Lin X,Y ang X,et al.NFATc4is negatively regulated in miR-133a-mediated cardiomyocyte hypert rophic repression[J].Am J Physiol Heart Circ Physiol,2010,298(5):1340-1347.
• [31]Duisters RF,Tijsen AJ,Schroen B,et al.miR-133and miR-30regulate connective tissue growth facto r:implications for a role of microRNAs in myocardial matrix remodeling[J].Circ Res,2009,104(2):170-178.
• [32]Care A,Catalucci D,Felicetti F,et al.MicroRNA-133controls cardiac hypertrophy[J].Nat Med,2007,13(5):613-618.
• [33]Costa Martins PA,Leptidis S,Salic K,et al.MicroRNA regulation in cardiovascular disease[J].Curr Drug Targets,2010,11(8):900-906.
• [34]Wang K,Long B,Zhou J,et al.miR-9and NFATc3regulate myocardin in cardiac hypertrophy[J].J Biol Chem,2010,285(16):11903-11912.
• [35]Yang Y,Ago T,Zhai P,et al.Thioredoxin1negativel y regu-latesangiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7[J].Circ Res,2011,108(3):305-313.
• [36]Callis TE,Pandya K,Seok HY,et al.MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice[J].J Clin Invest,2009,119(9):2772-2786.
• [37]Rane S,He M,Sayed D,et al.Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin1and recapit-ulates hypoxia preconditioning in cardiac myocytes[J].Circ Res,2009,104(7):879-886.
• [38]Busk PK,Cirera S.MicroRNA pro filing in early hypert rophic growth of the left ventricle in rats[J].Biochem Biophys Res Commun,2010,396(4):989-993.
• [39]Gwack Y,Sharma S,Nardone J,et al.A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT[J].Nature,2006,441(7093):646-650.
• [40]Hoofnagle MH,Neppl RL,Berzin EL,et al.Myocardin is differentially required for the devel-opment of smooth muscle cells and cardiomyocytes[J].Am J Physiol Heart Circ Physiol,2011,300(5):H1707-H1721.